NCT02159716View on ClinicalTrials.gov

CART-meso in Mesothelin Expressing Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Metastatic Pancreatic (Ductal) AdenocarcinomaEpithelial Ovarian CancerMalignant Epithelial Pleural Mesothelioma
Interventions
BIOLOGICAL

CART-meso

CART-meso are autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor SS1 fused to the 4-1BB and CD3ζ signaling domains.

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT02159716 - CART-meso in Mesothelin Expressing Cancers | Biotech Hunter | Biotech Hunter